• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
[(18)F]-FLT PET to predict early response to neoadjuvant therapy in KRAS wild-type rectal cancer: a pilot study.利用[（18）F]-氟代胸苷正电子发射断层扫描预测KRAS野生型直肠癌新辅助治疗的早期反应：一项初步研究
Ann Nucl Med. 2015 Jul;29(6):535-42. doi: 10.1007/s12149-015-0974-6. Epub 2015 Apr 22.
2
Assessment of response to neoadjuvant radiochemotherapy with F-18 FLT and F-18 FDG PET/CT in patients with rectal cancer.采用F-18 FLT和F-18 FDG PET/CT评估直肠癌患者对新辅助放化疗的反应
Ann Nucl Med. 2015 Apr;29(3):284-94. doi: 10.1007/s12149-014-0938-2. Epub 2014 Dec 11.
3
PET imaging with [18F]3'-deoxy-3'-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer.使用[18F]3'-脱氧-3'-氟胸苷进行正电子发射断层显像（PET）以预测直肠癌患者新辅助治疗的反应
Eur J Nucl Med Mol Imaging. 2007 Jun;34(6):878-83. doi: 10.1007/s00259-006-0292-2. Epub 2006 Dec 29.
4
Positron emission tomography with [(18)F]-3'-deoxy-3'fluorothymidine (FLT) as a predictor of outcome in patients with locally advanced resectable rectal cancer: a pilot study.正电子发射断层扫描（PET）用[(18)F]-3'-脱氧-3'氟胸苷（FLT）作为局部晚期可切除直肠癌患者预后的预测指标：一项初步研究。
Mol Imaging Biol. 2013 Feb;15(1):106-13. doi: 10.1007/s11307-012-0566-y.
5
3'-deoxy-3'-[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma: a pilot study to correlate imaging findings with tissue thymidine kinase 1 and Ki-67 activity and histopathologic response.3'-去氧-3'-[18F]氟代胸腺嘧啶正电子发射断层扫描用于软组织肉瘤反应评估：一项与组织胸苷激酶 1 和 Ki-67 活性及组织病理学反应相关的成像发现的初步研究。
Cancer. 2012 Jun 15;118(12):3135-44. doi: 10.1002/cncr.26630. Epub 2011 Oct 21.
6
3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.3'-去氧-3'-18F-氟代胸苷 PET/CT 引导表皮生长因子受体拮抗剂和 Bcl-xL 抑制剂治疗非小细胞肺癌。
J Nucl Med. 2012 Mar;53(3):443-50. doi: 10.2967/jnumed.111.096503. Epub 2012 Feb 13.
7
18F-FLT PET changes during radiotherapy combined with cetuximab in head and neck squamous cell carcinoma patients.18F-FLT PET在头颈部鳞状细胞癌患者放疗联合西妥昔单抗治疗过程中的变化
Nuklearmedizin. 2014;53(2):60-6. doi: 10.3413/Nukmed-0625-13-09. Epub 2014 Jan 28.
8
¹⁸F-FLT PET/CT as an imaging tool for early prediction of pathological response in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy: a pilot study.¹⁸F-FLT PET/CT作为新辅助化疗治疗局部晚期乳腺癌患者病理反应早期预测的成像工具：一项初步研究。
Eur J Nucl Med Mol Imaging. 2015 May;42(6):818-30. doi: 10.1007/s00259-015-2995-8. Epub 2015 Feb 12.
9
Depicting Changes in Tumor Biology in Response to Cetuximab Monotherapy or Combination Therapy by Apoptosis and Proliferation Imaging Using F-ICMT-11 and F-FLT PET.使用 F-ICMT-11 和 F-FLT PET 通过凋亡和增殖显像描绘西妥昔单抗单药或联合治疗对肿瘤生物学的影响变化。
J Nucl Med. 2018 Oct;59(10):1558-1565. doi: 10.2967/jnumed.118.209304. Epub 2018 May 24.
10
[18F]FLT-PET to predict pharmacodynamic and clinical response to cetuximab therapy in Ménétrier's disease.[18F]FLT-PET 预测 Menetrier 病患者接受西妥昔单抗治疗的药效动力学和临床反应。
Ann Nucl Med. 2012 Nov;26(9):757-63. doi: 10.1007/s12149-012-0636-x. Epub 2012 Jul 22.

引用本文的文献

1
Imaging and Metabolic Diagnostic Methods in the Stage Assessment of Rectal Cancer.直肠癌分期评估中的影像学和代谢诊断方法
Cancers (Basel). 2024 Jul 16;16(14):2553. doi: 10.3390/cancers16142553.
2
PET Oncological Radiopharmaceuticals: Current Status and Perspectives.正电子肿瘤放射药物学：现状与展望。
Molecules. 2022 Oct 11;27(20):6790. doi: 10.3390/molecules27206790.
3
PET/CT-Based Response Evaluation in Cancer-a Systematic Review of Design Issues.基于 PET/CT 的癌症疗效评估——设计问题的系统综述。
Mol Imaging Biol. 2020 Feb;22(1):33-46. doi: 10.1007/s11307-019-01351-4.
4
Intratumoral F-FLT infusion in metabolic targeted radiotherapy.代谢靶向放疗中的瘤内F-FLT注入
EJNMMI Res. 2019 Apr 11;9(1):33. doi: 10.1186/s13550-019-0496-7.
5
The use of 3'-deoxy-3'-F-fluorothymidine (FLT) PET in the assessment of long-term survival in breast cancer patients treated with neoadjuvant chemotherapy.使用 3'-去氧-3'-F-氟代胸苷（FLT）PET 评估新辅助化疗治疗的乳腺癌患者的长期生存。
Ann Nucl Med. 2019 Jun;33(6):383-393. doi: 10.1007/s12149-019-01345-w. Epub 2019 Feb 27.
6
FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab.FLT PET/CT 成像在接受 pTVG-HP DNA 疫苗和 pembrolizumab 治疗的转移性前列腺癌患者中的应用。
J Immunother Cancer. 2019 Jan 30;7(1):23. doi: 10.1186/s40425-019-0516-1.
7
Synthesis and Biological Evaluation of Novel (99m)Tc(CO)₃-Labeled Thymidine Analogs as Potential Probes for Tumor Proliferation Imaging.新型（99m）Tc（CO）₃标记的胸苷类似物作为肿瘤增殖显像潜在探针的合成与生物学评价
Molecules. 2016 Apr 19;21(4):510. doi: 10.3390/molecules21040510.
8
Mouse Models of Breast Cancer: Platforms for Discovering Precision Imaging Diagnostics and Future Cancer Medicine.乳腺癌小鼠模型：发现精准影像诊断和未来癌症医学的平台。
J Nucl Med. 2016 Feb;57 Suppl 1(Suppl 1):60S-8S. doi: 10.2967/jnumed.115.157917.

本文引用的文献

1
3'-Deoxy-3'-[18F]-Fluorothymidine PET imaging reflects PI3K-mTOR-mediated pro-survival response to targeted therapy in colorectal cancer.3'-脱氧-3'-[18F]-氟胸苷正电子发射断层显像反映了PI3K-mTOR介导的结直肠癌对靶向治疗的促生存反应。
PLoS One. 2014 Sep 23;9(9):e108193. doi: 10.1371/journal.pone.0108193. eCollection 2014.
2
Limits of [18F]-FLT PET as a biomarker of proliferation in oncology.[18F]-FLT PET 作为肿瘤增殖生物标志物的局限性。
PLoS One. 2013;8(3):e58938. doi: 10.1371/journal.pone.0058938. Epub 2013 Mar 15.
3
[18F]FLT-PET to predict pharmacodynamic and clinical response to cetuximab therapy in Ménétrier's disease.[18F]FLT-PET 预测 Menetrier 病患者接受西妥昔单抗治疗的药效动力学和临床反应。
Ann Nucl Med. 2012 Nov;26(9):757-63. doi: 10.1007/s12149-012-0636-x. Epub 2012 Jul 22.
4
Positron emission tomography with [(18)F]-3'-deoxy-3'fluorothymidine (FLT) as a predictor of outcome in patients with locally advanced resectable rectal cancer: a pilot study.正电子发射断层扫描（PET）用[(18)F]-3'-脱氧-3'氟胸苷（FLT）作为局部晚期可切除直肠癌患者预后的预测指标：一项初步研究。
Mol Imaging Biol. 2013 Feb;15(1):106-13. doi: 10.1007/s11307-012-0566-y.
5
Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials.对黑色素瘤进行常规多重突变分析可使患者入组到基于基因分型的治疗试验中。
PLoS One. 2012;7(4):e35309. doi: 10.1371/journal.pone.0035309. Epub 2012 Apr 20.
6
[(18)F]FLT: an imaging biomarker of tumour proliferation for assessment of tumour response to treatment.(18)F]FLT：肿瘤增殖的影像学生物标志物，用于评估肿瘤对治疗的反应。
Eur J Cancer. 2012 Mar;48(4):416-24. doi: 10.1016/j.ejca.2011.11.035. Epub 2011 Dec 29.
7
[(18)F]FLT-PET imaging does not always "light up" proliferating tumor cells.（18）F]FLT-PET 成像并不总是能“点亮”增殖的肿瘤细胞。
Clin Cancer Res. 2012 Mar 1;18(5):1303-12. doi: 10.1158/1078-0432.CCR-11-1433. Epub 2011 Dec 14.
8
A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer.一种用于快速检测非小细胞肺癌中与靶向治疗相关的多种致癌突变的平台。
J Mol Diagn. 2011 Jan;13(1):74-84. doi: 10.1016/j.jmoldx.2010.11.010. Epub 2010 Dec 23.
9
Effect of radiotherapy and chemotherapy on bone marrow activity: a 18F-FLT-PET study.放疗和化疗对骨髓活性的影响：一项18F-FLT-PET研究。
Nucl Med Commun. 2011 Jan;32(1):17-22. doi: 10.1097/mnm.0b013e328340798c.
10
18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model.18F-FLT PET 作为依维莫司抑制顺铂耐药卵巢肿瘤模型中 mTOR 时药物疗效的替代标志物。
J Nucl Med. 2010 Oct;51(10):1559-64. doi: 10.2967/jnumed.109.073288. Epub 2010 Sep 16.

利用[（18）F]-氟代胸苷正电子发射断层扫描预测KRAS野生型直肠癌新辅助治疗的早期反应：一项初步研究

[(18)F]-FLT PET to predict early response to neoadjuvant therapy in KRAS wild-type rectal cancer: a pilot study.

作者信息

McKinley Eliot T, Watchmaker Jennifer M, Chakravarthy A Bapsi, Meyerhardt Jeffrey A, Engelman Jeffrey A, Walker Ronald C, Washington M Kay, Coffey Robert J, Manning H Charles

机构信息

Vanderbilt University Institute of Imaging Science (VUIIS), Vanderbilt University Medical School, 1161 21st Ave. S., AA1105 MCN, Nashville, TN, 37232-2310, USA.

出版信息

Ann Nucl Med. 2015 Jul;29(6):535-42. doi: 10.1007/s12149-015-0974-6. Epub 2015 Apr 22.

DOI:10.1007/s12149-015-0974-6
PMID:25899481
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4503488/
Abstract

OBJECT

This pilot study evaluated the utility of 3'-deoxy-3'[18F]-fluorothymidine ([(18)F]-FLT) positron emission tomography (PET) to predict response to neoadjuvant therapy that included cetuximab in patients with wild-type KRAS rectal cancers.

METHODS

Baseline [(18)F]-FLT PET was collected prior to treatment initiation. Follow-up [(18)F]-FLT was collected after three weekly infusions of cetuximab, and following a combined regimen of cetuximab, 5-FU, and radiation. Imaging-matched biopsies were collected with each PET study.

RESULTS

Diminished [(18)F]-FLT PET was observed in 3/4 of patients following cetuximab treatment alone and in all patients following combination therapy. Reduced [(18)F]-FLT PET following combination therapy predicted disease-free status at surgery. Overall, [(18)F]-FLT PET agreed with Ki67 immunoreactivity from biopsy samples and surgically resected tissue, and was predictive of treatment-induced rise in p27 levels.

CONCLUSION

These results suggest that [(18)F]-FLT PET is a promising imaging biomarker to predict response to neoadjuvant therapy that included EGFR blockade with cetuximab in patients with rectal cancer.

摘要

目的

本初步研究评估了3'-脱氧-3'[18F]-氟胸腺嘧啶核苷（[(18)F]-FLT）正电子发射断层扫描（PET）在预测野生型KRAS直肠癌患者对含西妥昔单抗的新辅助治疗反应中的效用。

方法

在开始治疗前收集基线[(18)F]-FLT PET。在每周输注3次西妥昔单抗后，以及在西妥昔单抗、5-氟尿嘧啶和放疗联合方案治疗后收集随访[(18)F]-FLT。每次PET检查时均采集影像匹配的活检样本。

结果

单独使用西妥昔单抗治疗后，3/4的患者[(18)F]-FLT PET信号减弱，联合治疗后的所有患者均如此。联合治疗后[(18)F]-FLT PET信号减弱可预测手术时的无病状态。总体而言，[(18)F]-FLT PET与活检样本及手术切除组织中的Ki67免疫反应性一致，并可预测治疗引起的p27水平升高。

结论

这些结果表明，[(18)F]-FLT PET是一种有前景的成像生物标志物，可用于预测直肠癌患者对含西妥昔单抗的表皮生长因子受体阻断新辅助治疗的反应。